Linda Harrison1, Ann Melvin, Susan Fiscus, Yacine Saidi, Eleni Nastouli, Lynda Harper, Alexandra Compagnucci, Abdel Babiker, Ross McKinney, Diana Gibb, Gareth Tudor-Williams. 1. *Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA; †Seattle Children's Hospital, Seattle, WA; ‡School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; §INSERM, SC10-US019, Paris, France; ‖University College London Hospitals, University College London, London, United Kingdom; ¶Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom; #Duke University Medical Center, Durham, NC; and **Imperial College London, London, United Kingdom.
Abstract
BACKGROUND: The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold. METHODS: PENPACT-1 had a 2 × 2 factorial design, randomizing HIV-infected children to start protease inhibitor (PI) versus nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART, and switch at a 1000 copies/mL versus 30,000 copies/mL threshold. Switch criteria were not achieving the threshold by week 24, confirmed rebound above the threshold thereafter, or Center for Disease Control and Prevention stage C event. Resistance tests were performed on samples ≥1000 copies/mL before switch, resuppression, and at 4-years/trial end. RESULTS:Sixty-seven children started PI-based ART and were randomized to switch at 1000 copies/mL (PI-1000), 64 PIs and 30,000 copies/mL (PI-30,000), 67 NNRTIs and 1000 copies/mL (NNRTI-1000), and 65 NNRTI and 30,000 copies/mL (NNRTI-30,000). Ninety-four (36%) children reached the 1000 copies/mL switch criteria during 5-year follow-up. In 30,000 copies/mL threshold arms, median time from 1000 to 30,000 copies/mL switch criteria was 58 (PI) versus 80 (NNRTI) weeks (P = 0.81). In NNRTI-30,000, more nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations accumulated than other groups. NNRTI mutations were selected before switching at 1000 copies/mL (23% NNRTI-1000, 27% NNRTI-30,000). Sixty-two children started abacavir + lamivudine, 166 lamivudine + zidovudine or stavudine, and 35 other NRTIs. The abacavir + lamivudine group acquired fewest NRTI mutations. Of 60 switched to second-line, 79% PI-1000, 63% PI-30,000, 64% NNRTI-1000, and 100% NNRTI-30,000 were <400 copies/mL 24 weeks later. CONCLUSIONS:Children on first-line NNRTI-based ART who were randomized to switch at a higher virologic threshold developed the most resistance, yet resuppressed on second-line. An abacavir + lamivudine NRTI combination seemed protective against development of NRTI resistance.
RCT Entities:
BACKGROUND: The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold. METHODS: PENPACT-1 had a 2 × 2 factorial design, randomizing HIV-infectedchildren to start protease inhibitor (PI) versus nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART, and switch at a 1000 copies/mL versus 30,000 copies/mL threshold. Switch criteria were not achieving the threshold by week 24, confirmed rebound above the threshold thereafter, or Center for Disease Control and Prevention stage C event. Resistance tests were performed on samples ≥1000 copies/mL before switch, resuppression, and at 4-years/trial end. RESULTS: Sixty-seven children started PI-based ART and were randomized to switch at 1000 copies/mL (PI-1000), 64 PIs and 30,000 copies/mL (PI-30,000), 67 NNRTIs and 1000 copies/mL (NNRTI-1000), and 65 NNRTI and 30,000 copies/mL (NNRTI-30,000). Ninety-four (36%) children reached the 1000 copies/mL switch criteria during 5-year follow-up. In 30,000 copies/mL threshold arms, median time from 1000 to 30,000 copies/mL switch criteria was 58 (PI) versus 80 (NNRTI) weeks (P = 0.81). In NNRTI-30,000, more nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations accumulated than other groups. NNRTI mutations were selected before switching at 1000 copies/mL (23% NNRTI-1000, 27% NNRTI-30,000). Sixty-two children started abacavir + lamivudine, 166 lamivudine + zidovudine or stavudine, and 35 other NRTIs. The abacavir + lamivudine group acquired fewest NRTI mutations. Of 60 switched to second-line, 79% PI-1000, 63% PI-30,000, 64% NNRTI-1000, and 100% NNRTI-30,000 were <400 copies/mL 24 weeks later. CONCLUSIONS:Children on first-line NNRTI-based ART who were randomized to switch at a higher virologic threshold developed the most resistance, yet resuppressed on second-line. An abacavir + lamivudine NRTI combination seemed protective against development of NRTI resistance.
Authors: Victoria A Johnson; Francoise Brun-Vezinet; Bonaventura Clotet; Huldrych F Gunthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman Journal: Top HIV Med Date: 2009-12
Authors: Steve Welch; Mike Sharland; E G Hermione Lyall; Gareth Tudor-Williams; Tim Niehues; Uwe Wintergerst; Torsak Bunupuradah; Marc Hainaut; Marinella Della Negra; Maria José Mellado Pena; José Tomas Ramos Amador; Guido Castelli Gattinara; Alexandra Compagnucci; Albert Faye; Carlo Giaquinto; Diana M Gibb; Kate Gandhi; Silvia Forcat; Karen Buckberry; Lynda Harper; Christoph Königs; Deepak Patel; Diane Bastiaans Journal: HIV Med Date: 2009-11 Impact factor: 3.180
Authors: Diana M Gibb; A Sarah Walker; Steve Kaye; Anita De Rossi; Mounir Ait-Khaled; Deenan Pillay; Maria Angeles Muñoz-Fernandez; Clive Loveday; Alexandra Compagnucci; David T Dunn; Abdel G Babiker Journal: Antivir Ther Date: 2002-12
Authors: Alina S Bergshoeff; Pieter L A Fraaij; Annemarie M C van Rossum; Tom F W Wolfs; Sibyl P M Geelen; Ronald de Groot; David M Burger Journal: Antivir Ther Date: 2003-06
Authors: Alessandro Cozzi-Lepri; Andrew N Phillips; Lidia Ruiz; Bonaventura Clotet; Clive Loveday; Jesper Kjaer; Helene Mens; Nathan Clumeck; Ludmila Viksna; Francisco Antunes; Ladislav Machala; Jens D Lundgren Journal: AIDS Date: 2007-03-30 Impact factor: 4.177
Authors: Sharon A Riddler; Hongyu Jiang; Allan Tenorio; Hairong Huang; Daniel R Kuritzkes; Edward P Acosta; Alan Landay; Barbara Bastow; David W Haas; Karen T Tashima; Mamta K Jain; Steven G Deeks; John A Bartlett Journal: Antivir Ther Date: 2007
Authors: Kara Wools-Kaloustian; Irene Marete; Samuel Ayaya; Annette H Sohn; Lam Van Nguyen; Shanshan Li; Valériane Leroy; Beverly S Musick; Jamie E Newman; Andrew Edmonds; Mary-Ann Davies; François T Eboua; Marie-Thérèse Obama; Marcel Yotebieng; Shobna Sawry; Lynne M Mofenson; Constantin T Yiannoutsos Journal: J Acquir Immune Defic Syndr Date: 2018-06-01 Impact factor: 3.731
Authors: Dwight E Yin; Christina Ludema; Stephen R Cole; Carol E Golin; William C Miller; Meredith G Warshaw; Ross E McKinney Journal: PLoS One Date: 2020-11-23 Impact factor: 3.240
Authors: Alexander J Szubert; Andrew J Prendergast; Moira J Spyer; Victor Musiime; Philippa Musoke; Mutsa Bwakura-Dangarembizi; Patricia Nahirya-Ntege; Margaret J Thomason; Emmanuel Ndashimye; Immaculate Nkanya; Oscar Senfuma; Boniface Mudenge; Nigel Klein; Diana M Gibb; A Sarah Walker Journal: PLoS Med Date: 2017-11-14 Impact factor: 11.069